{
    "nct_id": "NCT00377715",
    "title": "Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2015-11-09",
    "description_brief": "This study will evaluate the safety and potential benefit of Dimebon as compared to placebo in patients with mild to moderate Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests oral Dimebon in mild\u2013moderate Alzheimer\u2019s disease to evaluate safety and potential benefit \u2014 language consistent with assessing symptomatic/cognitive benefit rather than a specific anti-amyloid or anti-tau biologic approach. Dimebon (latrepirdine) is a small\u2011molecule, repurposed Russian antihistamine with proposed multi\u2011target neuroprotective and neurotransmitter\u2011modulating effects (NMDA modulation, mitochondrial effects, autophagy modulation), not a monoclonal antibody or vaccine. \ue200cite\ue202turn0search6\ue202turn0search7\ue201.",
        "Act: Key extracted details \u2014 drug name and type: Dimebon (also called latrepirdine), an oral small molecule originally used as an antihistamine. The Phase 2 trial you provided is a double\u2011blind, placebo\u2011controlled study testing safety and potential benefit in mild\u2013moderate AD. Early phase trials reported cognitive improvements but later larger trials failed to confirm efficacy. Given Dimebon\u2019s small\u2011molecule nature and the trial\u2019s framing (safety and potential benefit on clinical outcomes), the most appropriate category is Cognitive enhancer (a small molecule evaluated for improving cognition/symptoms rather than a biologic explicitly targeting amyloid/tau). \ue200cite\ue202turn0search6\ue202turn0search1\ue202turn0search2\ue201.",
        "Reflect: Verification and caveats \u2014 classification as a Cognitive enhancer is supported because Dimebon is a small molecule with proposed symptomatic/neuroprotective actions and was developed/trialed for cognitive improvement; its mechanisms (autophagy, mitochondrial, receptor modulation) are heterogeneous and not a clearly defined disease\u2011targeting mechanism like anti\u2011amyloid or anti\u2011tau biologics, so it does not fit the \"disease\u2011targeted biologic\" category. Some preclinical work suggested effects on protein clearance (autophagy) that could be interpreted as disease\u2011modifying, but clinical evidence did not establish disease\u2011targeting efficacy and larger trials were negative \u2014 therefore Cognitive enhancer is the best fit while noting mechanistic ambiguity. \ue200cite\ue202turn0search0\ue202turn0search3\ue202turn0search5\ue201.",
        "Web search results (selected sources used to identify drug and mechanism): 1) \"The rise and fall of Dimebon\" \u2014 overview of Dimebon/latrepirdine history, origin as antihistamine, phase II promise and phase III failure. \ue200cite\ue202turn0search6\ue201. 2) Review on molecular mechanisms: latrepirdine affects mitochondria, autophagy, ion channels and multiple receptors (multi\u2011target small molecule). \ue200cite\ue202turn0search7\ue201. 3) Molecular Neurodegeneration study reporting effects on extracellular amyloid\u2011beta with acute dosing (mechanistic/biomarker data). \ue200cite\ue202turn0search1\ue201. 4) PubMed article reporting latrepirdine promotes autophagy and reduces intracellular A\u03b2 in model systems. \ue200cite\ue202turn0search0\ue201. 5) Cochrane review summarizing clinical trials: overall no consistent effect on cognition, possible modest benefit for behaviour; safety profile discussed. \ue200cite\ue202turn0search2\ue201."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The Phase 2 trial tests Dimebon (latrepirdine), an oral small molecule developed/repurposed as a cognitive enhancer for mild\u2013moderate AD. Its clinical framing (symptomatic/cognitive benefit) and known pharmacology (antihistamine origin, modulation of multiple neurotransmitter receptors including reported NMDA/ion\u2011channel effects) point primarily to neurotransmitter receptor modulation rather than a focused anti\u2011amyloid or anti\u2011tau biologic approach.",
        "Act: Key extracted details \u2014 drug: Dimebon (latrepirdine), oral small molecule; trial purpose: evaluate safety and potential cognitive benefit in mild\u2013moderate AD; mechanism: multi\u2011target but prominently reported to modulate neurotransmitter receptors (NMDA and others) and act as an antihistamine, with additional proposed mitochondrial and autophagy effects. Given the symptomatic/cognitive intent and receptor modulation, the most specific CADRO match is D) Neurotransmitter Receptors. Note: because Dimebon has heterogeneous mechanisms (mitochondrial, autophagy, receptor modulation), one could alternatively consider R) Multi\u2011target, but the clinical positioning as a cognitive enhancer and its receptor actions favor D.",
        "Reflect: Verification and caveats \u2014 classification aligns with CADRO definitions: symptomatic cognitive enhancers that act via receptor modulation map best to D) Neurotransmitter Receptors. However, mechanistic ambiguity (mitochondrial/proteostasis/autophagy effects; some preclinical amyloid effects) means R) Multi\u2011target is a reasonable secondary interpretation if emphasizing all mechanisms equally. Because the trial was chiefly symptomatic and Dimebon\u2019s receptor activity is prominent in the literature, D) is the preferred, most specific category.",
        "Web search results (sources summarized from your provided items): 1) Historical overview: \u201cThe rise and fall of Dimebon\u201d \u2014 origin as antihistamine, initial Phase II cognitive promise, later Phase III failure. 2) Reviews of molecular mechanisms: latrepirdine affects mitochondria, autophagy, ion channels and multiple receptors (multi\u2011target small molecule). 3) Preclinical reports: acute dosing studies showing effects on extracellular amyloid\u2011beta in model systems. 4) Studies showing promotion of autophagy and reduction of intracellular A\u03b2 in models. 5) Systematic reviews/Cochrane summaries: clinical trial meta\u2011analyses showing no consistent cognitive benefit in larger trials. These support the assignment to neurotransmitter/receptor modulation as the primary clinical mechanism while noting broader multi\u2011target activities."
    ]
}